DBV Technologies (DBVT) Cash from Investing Activities (2020 - 2026)
DBV Technologies (DBVT) reported Cash from Investing Activities of -$300000.0 for Q1 2026, up 25.0% year-over-year from -$240000.0 in Q1 2025, and up 58.04% quarter-over-quarter from -$715000.0 in Q4 2025.
DBV Technologies (DBVT) Cash from Investing Activities (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of Cash from Investing Activities data on file, last reported at -$300000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$300000.0, up 25.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 230.15% YoY), and the FY2025 annual result was -$1.4 million, down 80.85% from the prior year.
- Cash from Investing Activities grew to -$300000.0 in Q1 2026 per DBVT's latest filing, from -$715000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $793000.0 in Q4 2024 and troughed at -$2.1 million in Q1 2024.
- A 5-year average of -$196117.6 and a median of -$187000.0 in 2023 frame the typical range for Cash from Investing Activities.
- On a YoY basis, Cash from Investing Activities climbed as much as 524.06% in 2024 and fell as far as 5176.19% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$34000.0 in 2022, then sank by 450.0% to -$187000.0 in 2023, then soared by 524.06% to $793000.0 in 2024, then plunged by 190.16% to -$715000.0 in 2025, then soared by 58.04% to -$300000.0 in 2026.
- Business Quant data shows DBVT's Cash from Investing Activities at -$300000.0 in Q1 2026, -$715000.0 in Q4 2025, and -$241000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | -300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -300,000.00 |
| Mar 31, 2026 | -300,000.00 |
| Dec 31, 2025 | -715,000.00 |
| Dec 31, 2025 | -715,000.00 |
| Sep 30, 2025 | -241,000.00 |
| Sep 30, 2025 | -241,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -400,000.00 |
| Mar 31, 2025 | -400,000.00 |
| Dec 31, 2024 | 793,000.00 |
| Dec 31, 2024 | 793,000.00 |
| Sep 30, 2024 | -109,000.00 |
| Sep 30, 2024 | -109,000.00 |
| Jun 30, 2024 | 691,000.00 |
| Jun 30, 2024 | 691,000.00 |
| Mar 31, 2024 | -2.13 Mn |
| Mar 31, 2024 | -2.13 Mn |
| Dec 31, 2023 | -187,000.00 |
| Dec 31, 2023 | -187,000.00 |